Lipum has successfully completed its phase I clinical study with positive results. The study confirms that the drug candidate SOL-116 is safe, exhibits the expected pharmacokinetics, and effectively inhibits the target protein BSSL in both healthy volunteers and patients with rheumatoid arthritis. Additionally, the findings suggest that a once-monthly administration is an optimal dosing regimen. The company's CMO, Peter Hovstadius, discusses the results in an interview.